Rumor has it that the big dog pharmaceutical companies are the same everywhere you look, and Canada is no different. The fact is they don’t care how many people die or how many lives could be saved if there is no profit for them. In other words suppose someone may have developed a cure for cancer, thus cutting their profits, do you think they would step up to the plate and assist in the research? Read this story and find out, but be sure to check out the link at the bottom of this story to find out if this is fact or fiction:

On April 12, 1955, the first successful polio vaccine was administered to almost 2 million schoolchildren around the country. Its discoverer, University of Pittsburgh medical researcher Jonas Salk, was interviewed on CBS Radio that evening.

“Who owns the patent on this vaccine?” radio host Edward R. Murrow asked him.

It was a reasonable question, considering that immunity to a deadly disease that afflicted 300,000 Americans annually ought to be worth something.

“Well, the people, I would say,” Salk famously replied. “There is no patent. Could you patent the sun?”

In a world where the cancer drug Avastin — patented by the pharmaceutical company Genentech/Roche — costs patients about $80,000 per year without having been proven to extend lives, Salk’s selflessness has made him the hero of many medical researchers today.

One of Salk’s admirers is Evangelos Michelakis, a cancer researcher at the University of Alberta who, three years ago, discovered that a common, nontoxic chemical known as DCA, short for dichloroacetate, seems to inhibit the growth of cancerous tumors in mice. Michelakis’ initial findings garnered much fanfare at the time and have recirculated on the Web again this week, in large part because of a blog post (“Scientists cure cancer, but no one takes notice”) that ignited fresh debate with people wondering if it was true.

The mechanism by which DCA works in mice is remarkably simple: It killed most types of cancer cells by disrupting the way they metabolize sugar, causing them to self-destruct without adversely affecting normal tissues.

Following the animal trials, Michelakis and his colleagues did tests of DCA on human cancer cells in a Petri dish, then conducted human clinical trials using $1.5 million in privately raised funds. His encouraging results — DCA treatment appeared to extend the lives of four of the five study participants — were published last year in Science Translational Medicine.